主页 文献库文献详情
PMID: 24136669 已发表 · ppublish 英语

The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation.

Breast cancer research and treatment ·第 142 卷 ·第 1 期 ·2014-06-09

Valentini Adriana, Lubinski Jan, Byrski Tomasz, Ghadirian Parviz, Moller Pal, Lynch Henry T, Ainsworth Peter, Neuhausen Susan L, Weitzel Jeffrey, Singer Christian F, Olopade Olufunmilayo I, Saal Howard, Lyonnet Dominique Stoppa, Foulkes William D, Kim-Sing Charmaine, Manoukian Siranoush, Zakalik Dana, Armel Susan, Senter Leigha, Eng Charis, Grunfeld Eva, Chiarelli Anna M, Poll Aletta, Sun Ping, Narod Steven A,

摘要

Physicians are often approached by young women with a BRCA mutation and a recent history of breast cancer who wish to have a baby. They wish to know if pregnancy impacts upon their future risks of cancer recurrence and survival. To date, there is little information on the survival experience of women who carry a mutation in one of the BRCA genes and who become pregnant. From an international multi-center cohort study of 12,084 women with a BRCA1 or BRCA2 mutation, we identified 128 case subjects who were diagnosed with breast cancer while pregnant or who became pregnant after a diagnosis of breast cancer. These women were age-matched to 269 mutation carriers with breast cancer who did not become pregnant (controls). Subjects were followed from the date of breast cancer diagnosis until the date of last follow-up or death from breast cancer. The Kaplan-Meier method was used to estimate 15-year survival rates. The hazard ratio for survival associated with pregnancy was calculated using a left-truncated Cox proportional hazard model, adjusting for other prognostic factors. Among women who were diagnosed with breast cancer when pregnant or who became pregnant thereafter, the 15-year survival rate was 91.5 %, compared to a survival of 88.6 % for women who did not become pregnant (adjusted hazard ratio = 0.76; 95 % CI 0.31-1.91; p = 0.56). Pregnancy concurrent with or after a diagnosis of breast cancer does not appear to adversely affect survival among BRCA1/2 mutation carriers.

文献信息
期刊
Breast cancer research and treatment
期刊简称
Breast Cancer Res Treat
发表日期
2014-06-09
收录日期
2013-11-07
更新日期
2016-10-19
语言
英语
国家/地区
Netherlands
NLM ID
8111104
分析服务
分析服务

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: product@genelibs.com